Company
Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd)
Develops inhaled splice-switching oligonucleotide (RNA) drugs aimed at the RAGE receptor, the receptor for advanced glycation end-products. Lead candidate RB042 inhibits full-length RAGE while increasing the soluble decoy form esRAGE in the lung, with the goal of damping chronic airway inflammation. It is in a Phase 1 trial (NCT07285122) in healthy volunteers and healthy smokers, targeting COPD; the stated pipeline also covers alpha-1 antitrypsin deficiency, neutrophilic asthma and idiopathic pulmonary fibrosis. The longevity relevance is mechanistic rather than claimed by the company: RAGE-AGE signalling sits at the intersection of two recognised ageing hallmarks, chronic sterile inflammation and the accumulation of glycation end-products, and the company itself positions RB042 as a respiratory disease drug, not an ageing intervention. Note the company was spun out as RAGE Biotech, jointly founded with IP Group Australia, Monash University, Murdoch University, the University of Western Australia, and the Baker and Perron institutes, and now operates as Atisama Therapeutics.
At a glance
- Listing
- Private, not listed
- Category
- Pharma
- Headquarters
- Melbourne, Victoria, Australia
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- Pharma
- Market
- Australia
- Recent inflection
- 15 May 2026: now operating as Atisama Therapeutics, the company announced RB042 had advanced into multiple ascending dose cohorts of its Phase 1 trial after completing three of four single ascending dose cohorts, with readouts expected in H2 2026, and appointed Bernard Coulie as Chair of the Board (source: Atisama press release carried by FNArena, 16 May 2026). This followed the A$29m Series A announced 13 November 2025, led by IP Group Australia and Hostplus with Monash Ventures.
- Services
- None recorded
- People tracked
- 2
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | Unlisted |
| Ticker | None |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Private |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Melbourne, Victoria, Australia
- Website
- www.startupdaily.net
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
People
Who variis tracks here (2)
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
What moved lately
15 May 2026: now operating as Atisama Therapeutics, the company announced RB042 had advanced into multiple ascending dose cohorts of its Phase 1 trial after completing three of four single ascending dose cohorts, with readouts expected in H2 2026, and appointed Bernard Coulie as Chair of the Board (source: Atisama press release carried by FNArena, 16 May 2026). This followed the A$29m Series A announced 13 November 2025, led by IP Group Australia and Hostplus with Monash Ventures.
Common questions
- Why does variis track Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd)?
- Develops inhaled splice-switching oligonucleotide (RNA) drugs aimed at the RAGE receptor, the receptor for advanced glycation end-products. Lead candidate RB042 inhibits full-length RAGE while increasing the soluble decoy form esRAGE in the lung, with the goal of damping chronic airway inflammation. It is in a Phase 1 trial (NCT07285122) in healthy volunteers and healthy smokers, targeting COPD; the stated pipeline also covers alpha-1 antitrypsin deficiency, neutrophilic asthma and idiopathic pulmonary fibrosis. The longevity relevance is mechanistic rather than claimed by the company: RAGE-AGE signalling sits at the intersection of two recognised ageing hallmarks, chronic sterile inflammation and the accumulation of glycation end-products, and the company itself positions RB042 as a respiratory disease drug, not an ageing intervention. Note the company was spun out as RAGE Biotech, jointly founded with IP Group Australia, Monash University, Murdoch University, the University of Western Australia, and the Baker and Perron institutes, and now operates as Atisama Therapeutics.
- Is Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd) publicly listed?
- variis has no ticker on file for Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd), so it is tracked as private or unlisted. Absence of a ticker on this record is not a statement that no listing exists anywhere.
- Where is Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd) based?
- Melbourne, Victoria, Australia
- Is Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd) still trading?
- Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd) is recorded as private.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
Every entity profile on variis is sourced. Not investment advice.